Educational guide
Pathological and therapeutic roles of bioactive peptide ...
Muskett F, May F, Westley B, Feeney J. Solution structure of the disulfide-linked dimer of human intestinal trefoil factor (TFF3): the intermolecular orientation and interactions are markedly different from those of other dimeric trefoil proteins. Biochemistry
This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.
Muskett F, May F, Westley B, Feeney J. Solution structure of the disulfide-linked dimer of human intestinal trefoil factor (TFF3): the intermolecular orientation and interactions are markedly different from those of other dimeric trefoil proteins. Biochemistry. 2003;42:15139–47.
Prest S, May F, Westley B. The estrogen-regulated protein, TFF1, stimulates migration of human breast cancer cells. FASEB J. 2002;16:592–4.
Poulsen S, Kissow H, Hare K, Hartmann B, Thim L. Luminal and parenteral TFF2 and TFF3 dimer and monomer in two models of experimental colitis in the rat. Regulatory Pept. 2005;126:163–71.
Kinoshita K, Taupin D, Itoh H, Podolsky D. Distinct pathways of cell migration and antiapoptotic response to epithelial injury: structure-function analysis of human intestinal trefoil factor. Mol Cell Biol. 2000;20:4680–90.
Bernstein H, Dobrowolny H, Trübner K, Steiner J, Bogerts B, Hoffmann W. Differential regional and cellular distribution of TFF3 peptide in the human brain. Amino Acids. 2015;47:1053–63.
Srivatsa G, Giraud A, Ulaganathan M, Yeomans N, Dow C, Nicoll A. Biliary epithelial trefoil peptide expression is increased in biliary diseases. Histopathology. 2002;40:261–8.
Rinnert M, Hinz M, Buhtz P, Reiher F, Lessel W, Hoffmann W. Synthesis and localization of trefoil factor family (TFF) peptides in the human urinary tract and TFF2 excretion into the urine. Cell Tissue Res. 2010;339:639–47.
Jackerott M, Lee Y, Møllgård K, Kofod H, Jensen J, Rohleder S, et al. Trefoil factors are expressed in human and rat endocrine pancreas: differential regulation by growth hormone. Endocrinology. 2006;147:5752–9.
Poulsom R, Hanby A, Lalani E, Hauser F, Hoffmann W, Stamp G. Intestinal trefoil factor (TFF 3) and pS2 (TFF 1), but not spasmolytic polypeptide (TFF 2) mRNAs are co-expressed in normal, hyperplastic, and neoplastic human breast epithelium. J Pathol. 1997;183:30–38.
Wiede A, Jagla W, Welte T, Köhnlein T, Busk H, Hoffmann W. Localization of TFF3, a new mucus-associated peptide of the human respiratory tract. Am J Respir. Crit Care Med. 1999;159:1330–5.
Langer G, Jagla W, Behrens-Baumann W, Walter S, Hoffmann W. Secretory peptides TFF1 and TFF3 synthesized in human conjunctival goblet cells. Invest. Ophthalmol Vis Sci. 1999;40:2220–4.
Cook G, Familari M, Thim L, Giraud A. The trefoil peptides TFF2 and TFF3 are expressed in rat lymphoid tissues and participate in the immune response. FEBS Lett. 1999;456:155–9.
Taupin D, Podolsky D. Trefoil factors: initiators of mucosal healing. Nat Rev Mol Cell Biol. 2003;4:721–32.
Hoffmann W. Trefoil factor family (TFF) peptides and chemokine receptors: a promising relationship. J Med. Chem. 2009;52:6505–10.
Mashimo H, Wu D, Podolsky D, Fishman M. Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor. Science 1996;274:262–5.
Beck P, Wong J, Li Y, Swaminathan S, Xavier R, Devaney K, et al. Chemotherapy- and radiotherapy-induced intestinal damage is regulated by intestinal trefoil factor. Gastroenterology. 2004;126:796–808.
Paulsen F, Woon C, Varoga D, Jansen A, Garreis F, Jäger K, et al. Intestinal trefoil factor/TFF3 promotes re-epithelialization of corneal wounds. J Biol Chem. 2008;283:13418–27.
Shah A, Leidinger P, Keller A, Wendschlag A, Backes C, Baus-Loncar M, et al. The intestinal factor Tff3 and a miRNA network regulate murine caloric metabolism. RNA Biol. 2011;8:77–81.
Wu X, Zheng H, Yang R, Luan X, Zhang L, Jin Q, et al. Mouse trefoil factor 3 ameliorated high-fat-diet-induced hepatic steatosis via increasing peroxisome proliferator-activated receptor-α-mediated fatty acid oxidation. Am J Physiol Endocrinol Metab. 2019;317:E436–E445.
Kozina N, Mihaljević Z, Lončar M, Mihalj M, Mišir M, Radmilović M, et al. Tff3Impact of high salt diet on cerebral vascular function and stroke in C57BL/6N knockout and WT (C57BL/6N) control mice. Int J Mol Sci. 2019;20:5188.
Liu S, Roberts D, Zhang B, Ren Y, Zhang L, Wu Y. Trefoil factor 3 as an endocrine neuroprotective factor from the liver in experimental cerebral ischemia/reperfusion injury. PLoS ONE. 2013;8:e77732.
Mohammadi-Shemirani P, Sjaarda J, Gerstein H, Treleaven D, Walsh M, Mann J, et al. A mendelian randomization-based approach to identify early and sensitive diagnostic biomarkers of disease. Clin Chem. 2019;65:427–36.
Du T, Luo H, Qin H, Wang F, Wang Q, Xiang Y, et al. Circulating serum trefoil factor 3 (TFF3) is dramatically increased in chronic kidney disease. PloS one. 2013;8:e80271.
Astor B, Köttgen A, Hwang S, Bhavsar N, Fox C, Coresh J. Trefoil factor 3 predicts incident chronic kidney disease: a case-control study nested within the Atherosclerosis Risk in Communities (ARIC) study. Am J Nephrol. 2011;34:291–7.
Brott D, Furlong S, Adler S, Hainer J, Arani R, Pinches M, et al. Characterization of renal biomarkers for use in clinical trials: effect of preanalytical processing and qualification using samples from subjects with diabetes. Drug Des, Dev Ther. 2015;9:3191–8.
Roa GJB, Tortolero GS, Gonzalez JE. Trefoil factor 3 (TFF3) expression is regulated by insulin and glucose. J Health Sci. 2013; https://doi.org/10.17532/jhsci.2013.26.
Tran C, Familari M, Parker L, Whitehead R, Giraud A. Short-chain fatty acids inhibit intestinal trefoil factor gene expression in colon cancer cells. Am J Physiol. 1998;275:G85–94.
Xue Y, Shen L, Cui Y, Zhang H, Chen Q, Cui A, et al. Tff3, as a novel peptide, regulates hepatic glucose metabolism. PLoS ONE. 2013;8:e75240.
Ge H, Gardner J, Wu X, Rulifson I, Wang J, Xiong Y, et al. Trefoil factor 3 (TFF3) is regulated by food intake, improves glucose tolerance and induces mucinous metaplasia. PLoS ONE. 2015;10:e0126924.
Zhou F, Zhou J, Wang W, Zhang X, Ji Y, Zhang P, et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: a systematic review and meta-analysis. Hepatol (Baltim, Md). 2019;70:1119–33.
Guillén N, Navarro M, Arnal C, Noone E, Arbonés-Mainar J, Acín S, et al. Microarray analysis of hepatic gene expression identifies new genes involved in steatotic liver. Physiol Genomics. 2009;37:187–98.
Brown A, Olver W, Donnelly C, May M, Naggert J, Shaffer D, et al. Searching QTL by gene expression: analysis of diabesity. BMC Genet. 2005;6:12.
Bujak M, Bujak I, Sobočanec S, Mihalj M, Novak S, Ćosić A, et al. Trefoil factor 3 deficiency affects liver lipid metabolism. Cell Physiol Biochem. 2018;47:827–41.
Šešelja K, Bazina I, Welss J, Schicht M, Paulsen F, Bijelić N, et al. Effect of Tff3 deficiency and ER stress in the liver. Int J Mol Sci. 2019;20:4389.
Jagla W, Wiede A, Dietzmann K, Rutkowski K, Hoffmann W. Co-localization of TFF3 peptide and oxytocin in the human hypothalamus. FASEB J. 2000;14:1126–31.
Probst J, Zetzsche T, Weber M, Theilemann P, Skutella T, Landgraf R, et al. Human intestinal trefoil factor is expressed in human hypothalamus and pituitary: evidence for a novel neuropeptide. FASEB J. 1996;10:1518–23.
Paterson R, Bartlett J, Blennow K, Fox N, Shaw L, Trojanowski J, et al. Cerebrospinal fluid markers including trefoil factor 3 are associated with neurodegeneration in amyloid-positive individuals. Transl Psychiatry. 2014;4:e419.
Zou J, Chen Z, Liang C, Fu Y, Wei X, Lu J, et al. Trefoil factor 3, cholinesterase and homocysteine: potential predictors for Parkinson’s disease dementia and vascular Parkinsonism dementia in advanced stage. Aging Dis. 2018;9:51–65.
Lubka M, Müller M, Baus-Loncar M, Hinz M, Blaschke K, Hoffmann W, et al. Lack of Tff3 peptide results in hearing impairment and accelerated presbyacusis. Cell Physiol Biochem. 2008;21:437–44.
Lubka-Pathak M, Shah A, Gallozzi M, Müller M, Zimmermann U, Löwenheim H, et al. Altered expression of securin (Pttg1) and serpina3n in the auditory system of hearing-impaired Tff3-deficient mice. Cell Mol life Sci. 2011;68:2739–49.
Shi H, Zhu W, Liu J, Luo Y, Si J, Wang S, et al. PI3K/Akt signaling pathway in the basolateral amygdala mediates the rapid antidepressant-like effects of trefoil factor 3. Neuropsychopharmacology. 2012;37:2671–83.
Schwarzberg H, Kalbacher H, Hoffmann W. Differential behavioral effects of TFF peptides: injections of synthetic TFF3 into the rat amygdala. Pharmacol Biochem Behav. 1999;62:173–8.
Shi H, Yin X, Song L, Guo Q, Luo X. Neuropeptide trefoil factor 3 improves learning and retention of novel object recognition memory in mice. Behavioural Brain Res. 2012;227:265–9.
Li J, Luo Y, Zhang R, Shi H, Zhu W, Shi J. Neuropeptide trefoil factor 3 reverses depressive-like behaviors by activation of BDNF-ERK-CREB signaling in olfactory bulbectomized rats. Int J Mol Sci. 2015;16:28386–28400.
Arnold P, Rickert U, Helmers A, Spreu J, Schneppenheim J, Lucius R. Trefoil factor 3 shows anti-inflammatory effects on activated microglia. Cell tissue Res. 2016;365:3–11.
Luo Y, Han H, Shao J, Gao Y, Yin X, Zhu W, et al. mTOR signalling in the nucleus accumbens shell is critical for augmented effect of TFF3 on behavioural response to cocaine. Sci Rep. 2016;6:27895.
Wu P, Shi H, Luo Y, Zhang R, Li J, Shi J, et al. Neuropeptide trefoil factor 3 attenuates naloxone-precipitated withdrawal in morphine-dependent mice. Psychopharmacology. 2014;231:4659–68.
Lanas A, Chan F. Peptic ulcer disease. Lancet (Lond, Engl). 2017;390:613–24.
Longman R, Douthwaite J, Sylvester P, Poulsom R, Corfield A, Thomas M, et al. Coordinated localisation of mucins and trefoil peptides in the ulcer associated cell lineage and the gastrointestinal mucosa. Gut. 2000;47:792–800.
Kouznetsova I, Kalinski T, Meyer F, Hoffmann W. Self-renewal of the human gastric epithelium: new insights from expression profiling using laser microdissection. Mol Biosyst. 2011;7:1105–12.
Kouznetsova I, Peitz U, Vieth M, Meyer F, Vestergaard E, Malfertheiner P, et al. A gradient of TFF3 (trefoil factor family 3) peptide synthesis within the normal human gastric mucosa. Cell Tissue Res. 2004;316:155–65.
Alison M, Chinery R, Poulsom R, Ashwood P, Longcroft J, Wright N. Experimental ulceration leads to sequential expression of spasmolytic polypeptide, intestinal trefoil factor, epidermal growth factor and transforming growth factor alpha mRNAs in rat stomach. J Pathol. 1995;175:405–14.
Taupin D, Pedersen J, Familari M, Cook G, Yeomans N, Giraud A. Augmented intestinal trefoil factor (TFF3) and loss of pS2 (TFF1) expression precedes metaplastic differentiation of gastric epithelium. Lab Invest. 2001;81:397–408.
Chinery R, Playford R. Combined intestinal trefoil factor and epidermal growth factor is prophylactic against indomethacin-induced gastric damage in the rat. Clin Sci. 1995;88:401–3.
Babyatsky M, deBeaumont M, Thim L, Podolsky D. Oral trefoil peptides protect against ethanol- and indomethacin-induced gastric injury in rats. Gastroenterology. 1996;110:489–97.
Dignass A, Lynch-Devaney K, Kindon H, Thim L, Podolsky D. Trefoil peptides promote epithelial migration through a transforming growth factor beta-independent pathway. J Clin Invest. 1994;94:376–83.
Huang Y, Wang M, Yang Z, Ren Y, Zhang W, Sun Z, et al. viaPretreatment with intestinal trefoil factor alleviates stress-induced gastric mucosal damage Akt signaling. World J Gastroenterol. 2020;26:7619–32.
Yu H, He Y, Zhang X, Peng Z, Yang Y, Zhu R, et al. The rat IgGFcγBP and Muc2 C-terminal domains and TFF3 in two intestinal mucus layers bind together by covalent interaction. PLoS ONE. 2011;6:e20334.
Beck P, Ihara E, Hirota S, MacDonald J, Meng D, Nanthakumar N, et al. Exploring the interplay of barrier function and leukocyte recruitment in intestinal inflammation by targeting fucosyltransferase VII and trefoil factor 3. Am J Physiol Gastrointest liver Physiol. 2010;299:G43–53.
Madsen J, Sorensen G, Nielsen O, Tornøe I, Thim L, Fenger C, et al. A variant form of the human deleted in malignant brain tumor 1 (DMBT1) gene shows increased expression in inflammatory bowel diseases and interacts with dimeric trefoil factor 3 (TFF3). PLoS ONE. 2013;8:e64441.
Meyer zum Büschenfelde D, Tauber R, Huber O. TFF3-peptide increases transepithelial resistance in epithelial cells by modulating claudin-1 and -2 expression. Peptides. 2006;27:3383–90.
Buda A, Jepson M, Pignatelli M. Regulatory function of trefoil peptides (TFF) on intestinal cell junctional complexes. Cell Commun Adhes. 2012;19:63–68.
Aihara E, Engevik K, Montrose M. Trefoil factor peptides and gastrointestinal function. Annu Rev Physiol. 2017;79:357–80.
Lin N, Xu L, Sun M. The protective effect of trefoil factor 3 on the intestinal tight junction barrier is mediated by toll-like receptor 2 via a PI3K/Akt dependent mechanism. Biochem. Biophys. Res Commun. 2013;440:143–9.
Dürer U, Hartig R, Bang S, Thim L, Hoffmann W. TFF3 and EGF induce different migration patterns of intestinal epithelial cells in vitro and trigger increased internalization of E-cadherin. Cell Physiol Biochem. 2007;20:329–46.
Le J, Zhang D, Zhao Y, Qiu W, Wang P, Sun Y. ITF promotes migration of intestinal epithelial cells through crosstalk between the ERK and JAK/STAT3 pathways. Sci Rep. 2016;6:33014.
Podolsky D, Gerken G, Eyking A, Cario E. Colitis-associated variant of TLR2 causes impaired mucosal repair because of TFF3 deficiency. Gastroenterology. 2009;137:209–20.
Teng X, Xu L, Zhou P, Sun H, Sun M. Effects of trefoil peptide 3 on expression of TNF-alpha, TLR4, and NF-kappaB in trinitrobenzene sulphonic acid induced colitis mice. Inflammation. 2009;32:120–9.
Shi L, Zhou P, Xi J, Yu H, Zhang B. Recombinant human trefoil factor 3 ameliorates bowel injury: its anti-inflammatory effect on experimental necrotizing enterocolitis. Int J Pept. 2014;2014:634135.
Zhu Y, Tan X. TFF3 modulates NF-{kappa}B and a novel negative regulatory molecule of NF-{kappa}B in intestinal epithelial cells via a mechanism distinct from TNF-{alpha}. Am J Physiol Cell Physiol. 2005;289:C1085–1093.
Barrett K. A new twist on trefoils. Focus on “TFF3 modulates NF-{kappa}B and a novel regulatory molecule of NF-{kappa}B in intestinal epithelial cells via a mechanism distinct from TNF-{alpha}”. Am J Physiol Cell Physiol. 2005;289:C1069–1071.
Wang Y, Liang K, Kong W. Intestinal trefoil factor 3 alleviates the intestinal barrier function through reducing the expression of TLR4 in rats with nonalcoholic steatohepatitis. Arch Med Res. 2019;50:2–9.
Barrera G, Sanchez G, Gonzalez J. Trefoil factor 3 isolated from human breast milk downregulates cytokines (IL8 and IL6) and promotes human beta defensin (hBD2 and hBD4) expression in intestinal epithelial cells HT-29. Bosn J Basic Med Sci. 2012;12:256–64.
Barrera G, Tortolero G. Trefoil factor 3 (TFF3) from human breast milk activates PAR-2 receptors, of the intestinal epithelial cells HT-29, regulating cytokines and defensins. Bratisl Lek Listy. 2016;117:332–9.
Belle N, Ji Y, Herbine K, Wei Y, Park J, Zullo K, et al. TFF3 interacts with LINGO2 to regulate EGFR activation for protection against colitis and gastrointestinal helminths. Nat Commun. 2019;10:4408.
Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin. 2021;71:209–49.
Jahan R, Shah A, Kisling S, Macha M, Thayer S, Batra S, et al. Odyssey of trefoil factors in cancer: diagnostic and therapeutic implications. Biochim Biophys Acta Rev Cancer. 2020;1873:188362.
Chen R, Chiou Y, Chong Q, Poh H, Tan T, Zhang M, et al. Pharmacological inhibition of TFF3 enhances sensitivity of CMS4 colorectal carcinoma to 5-fluorouracil through inhibition of p44/42 MAPK. Int J Mol Sci. 2019;20:6215.
Lin X, Zhang H, Dai J, Zhang W, Zhang J, Xue G, et al. TFF3 Contributes to epithelial-mesenchymal transition (EMT) in papillary thyroid carcinoma cells via the MAPK/ERK signaling pathway. J Cancer. 2018;9:4430–9.
Storesund T, Hayashi K, Kolltveit K, Bryne M, Schenck K. Salivary trefoil factor 3 enhances migration of oral keratinocytes. Eur J oral Sci. 2008;116:135–40.
Furuta G, Turner J, Taylor C, Hershberg R, Comerford K, Narravula S, et al. Hypoxia-inducible factor 1-dependent induction of intestinal trefoil factor protects barrier function during hypoxia. J Exp Med. 2001;193:1027–34.
Zwaini Z, Alammari D, Byrne S, Stover C. Mode of proximal tubule damage: differential cause for the release of TFF3? Front Immunol. 2016;7:122.
Hernández C, Santamatilde E, McCreath K, Cervera A, Díez I, Ortiz-Masiá D, et al. Induction of trefoil factor (TFF)1, TFF2 and TFF3 by hypoxia is mediated by hypoxia inducible factor-1: implications for gastric mucosal healing. Br J Pharmacol. 2009;156:262–72.
Guleng B, Han J, Yang J, Huang Q, Huang J, Yang X, et al. TFF3 mediated induction of VEGF via hypoxia in human gastric cancer SGC-7901 cells. Mol Biol Rep. 2012;39:4127–34.
Sun Y, Wang L, Zhou Y, Mao X, Deng X. Human trefoil factor 3 induces the transcription of its own promoter through STAT3. Sci Rep. 2016;6:30421.
Pandey V, Wu Z, Zhang M, Li R, Zhang J, Zhu T, et al. Trefoil factor 3 promotes metastatic seeding and predicts poor survival outcome of patients with mammary carcinoma. Breast Cancer Res. 2014;16:429.
Pandey V, Zhang M, You M, Zhang W, Chen R, Zhang W, et al. Expression of two non-mutated genetic elements is sufficient to stimulate oncogenic transformation of human mammary epithelial cells. Cell Death Dis. 2018;9:1147.
Yuan Z, Chen D, Chen X, Yang H, Wei Y. Overexpression of trefoil factor 3 (TFF3) contributes to the malignant progression in cervical cancer cells. Cancer cell Int. 2017;17:7.
Rivat C, Christine R, Rodrigues S, Sylvie R, Bruyneel E, Erik B, et al. Implication of STAT3 signaling in human colonic cancer cells during intestinal trefoil factor 3 (TFF3)—and vascular endothelial growth factor-mediated cellular invasion and tumor growth. Cancer Res. 2005;65:195–202.
Lobie PE, Pandey VK, Subbegowda RK, Basappa B, Dhananjaya MC, Rangappa S. Compounds useful in inhibiting human trefoil factor 3. WO2018226155. Patent. 2018 Dec 13.
Poh H, Chiou Y, Chong Q, Chen R, Rangappa K, Ma L, et al. Inhibition of TFF3 enhances sensitivity-and overcomes acquired resistance-to doxorubicin in estrogen receptor-positive mammary carcinoma. Cancers (Basel);11:1528.
Zhang M, Wang B, Chong Q, Pandey V, Guo Z, Chen R, et al. A novel small-molecule inhibitor of trefoil factor 3 (TFF3) potentiates MEK1/2 inhibition in lung adenocarcinoma. Oncogenesis. 2019;8:65.
Hoffmann W, Jagla W, Wiede A. Molecular medicine of TFF-peptides: from gut to brain. Histol Histopathol. 2001;16:319–34.
Matsuoka Y, Pascall J, Brown K. Quantitative analysis reveals differential expression of mucin (MUC2) and intestinal trefoil factor mRNAs along the longitudinal axis of rat intestine. Biochim Biophys Acta. 1999;1489:336–44.
Kobayashi K, Ogata H, Morikawa M, Iijima S, Harada N, Yoshida T, et al. Distribution and partial characterisation of IgG Fc binding protein in various mucin producing cells and body fluids. Gut. 2002;51:169–76.
Albert T, Laubinger W, Müller S, Hanisch F, Kalinski T, Meyer F, et al. Human intestinal TFF3 forms disulfide-linked heteromers with the mucus-associated FCGBP protein and is released by hydrogen sulfide. J Proteome Res. 2010;9:3108–17.
Houben T, Harder S, Schlüter H, Kalbacher H, Hoffmann W. Different forms of TFF3 in the human saliva: heterodimerization with IgG Fc binding protein (FCGBP). Int J Mol Sci. 2019;20:5000.
Hoffmann W. Trefoil factor family (TFF) peptides and their diverse molecular functions in mucus barrier protection and more: changing the paradigm. Int J Mol Sci. 2020;21:4535.
Fosslien E. Review: molecular pathology of cyclooxygenase-2 in cancer-induced angiogenesis. Ann Clin Lab Sci. 2001;31:325–48.
Fukuda R, Kelly B, Semenza G. Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1. Cancer Res. 2003;63:2330–4.
Emami S, Le Floch N, Bruyneel E, Thim L, May F, Westley B, et al. Induction of scattering and cellular invasion by trefoil peptides in src- and RhoA-transformed kidney and colonic epithelial cells. FASEB J. 2001;15:351–61.
Rodrigues S, Nguyen Q, Faivre S, Bruyneel E, Thim L, Westley B, et al. Activation of cellular invasion by trefoil peptides and src is mediated by cyclooxygenase- and thromboxane A2 receptor-dependent signaling pathways. FASEB J. 2001;15:1517–28.
Loos M, De Creus A, Thim L, Remaut E, Rottiers P. Murine trefoil factor 3 does not directly modulate LPS-mediated dendritic cell function. Scand J Immunol. 2007;66:35–42.
Tan X, Chen Y, Liu Q, Gonzalez-Crussi F, Liu X. Prostanoids mediate the protective effect of trefoil factor 3 in oxidant-induced intestinal epithelial cell injury: role of cyclooxygenase-2. J Cell Sci. 2000:;113:2149-55.
Décaillot F, Kazmi M, Lin Y, Ray-Saha S, Sakmar T, Sachdev P. CXCR7/CXCR4 heterodimer constitutively recruits beta-arrestin to enhance cell migration. J Biol Chem. 2011;286:32188–97.
Dieckow J, Brandt W, Hattermann K, Schob S, Schulze U, Mentlein R, et al. CXCR4 and CXCR7 mediate TFF3-induced cell migration independently from the ERK1/2 signaling pathway. Invest Ophthalmol Vis Sci. 2016;57:56–65.
Liu D, el-Hariry I, Karayiannakis A, Wilding J, Chinery R, Kmiot W, et al. Phosphorylation of beta-catenin and epidermal growth factor receptor by intestinal trefoil factor. Lab Invest. 1997;77:557–63.
Baus-Loncar M, Giraud A. Multiple regulatory pathways for trefoil factor (TFF) genes. Cell Mol life Sci. 2005;62:2921–31.
LeSimple P, van Seuningen I, Buisine M, Copin M, Hinz M, Hoffmann W, et al. Trefoil factor family 3 peptide promotes human airway epithelial ciliated cell differentiation. Am J Respir Cell Mol Biol. 2007;36:296–303.
Fueger P, Schisler J, Lu D, Babu D, Mirmira R, Newgard C, et al. Trefoil factor 3 stimulates human and rodent pancreatic islet beta-cell replication with retention of function. Mol Endocrinol (Baltim, Md). 2008;22:1251–9.
Williams A, Jacobs S, Moreno-Macías H, Huerta-Chagoya A, Churchhouse C, Márquez-Luna C, et al. Sequence variants in SLC16A11 are a common risk factor for type 2 diabetes in Mexico. Nature. 2014;506:97–101.
Locke A, Kahali B, Berndt S, Justice A, Pers T, Day F, et al. Genetic studies of body mass index yield new insights for obesity biology. Nature. 2015;518:197–206.
Shungin D, Winkler T, Croteau-Chonka D, Ferreira T, Locke A, Mägi R, et al. New genetic loci link adipose and insulin biology to body fat distribution. Nature. 2015;518:187–96.
Su T, Ren Q, Lu Y, Tai W, Zhu Y, Li Z, et al. A genetic variant in LINGO2 contributes to the risk of gestational diabetes mellitus in a Chinese population. J Cell Physiol. 2019;234:7012–8.
Jo J, Park S, Park S, Lee H, Kim C, Jung D, et al. Novel gastric cancer stem cell-related marker LINGO2 is associated with cancer cell phenotype and patient outcome. Int J Mol Sci. 2019;20:555.
Mahmood A, Melley L, Fitzgerald A, Ghosh S, Playford R. Trial of trefoil factor 3 enemas, in combination with oral 5-aminosalicylic acid, for the treatment of mild-to-moderate left-sided ulcerative colitis. Alimentary Pharmacol Ther. 2005;21:1357–64.
Vandenbroucke K, Hans W, Van Huysse J, Neirynck S, Demetter P, Remaut E, et al. Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice. Gastroenterology. 2004;127:502–13.
Peterson D, Barker N, Akhmadullina L, Rodionova I, Sherman N, Davidenko I, et al. Phase II, randomized, double-blind, placebo-controlled study of recombinant human intestinal trefoil factor oral spray for prevention of oral mucositis in patients with colorectal cancer who are receiving fluorouracil-based chemotherapy. J Clin Oncol. 2009;27:4333–8.
Schulze U, Sel S, Paulsen F. Trefoil factor family peptide 3 at the ocular surface. A promising therapeutic candidate for patients with dry eye syndrome? Dev Ophthalmol. 2010;45:1–11.
Choudhary A, Smitha C, Suresh D. Trefoils: an unexplored natural protective shield of oral cavity. J Oral Biol Craniofacial Res. 2015;5:226–31.
dos Santos Silva E, Ulrich M, Döring G, Botzenhart K, Gött P. Trefoil factor family domain peptides in the human respiratory tract. J Pathol. 2000;190:133–42.
Schulze U, Hampel U, Sel S, Contreras-Ruiz L, Schicht M, Dieckow J, et al. Trefoil factor family peptide 3 (TFF3) is upregulated under experimental conditions similar to dry eye disease and supports corneal wound healing effects in vitro. Invest Ophthalmol Vis Sci. 2014;55:3037–42.
Madsen J, Nielsen O, Tornøe I, Thim L, Holmskov U. Tissue localization of human trefoil factors 1, 2, and 3. J Histochem Cytochem. 2007;55:505–13.
Paulsen F, Varoga D, Paulsen A, Tsokos M. Trefoil factor family (TFF) peptides of normal human Vater’s ampulla. Cell Tissue Res. 2005;321:67–74.
Jagla W, Wiede A, Hinz M, Dietzmann K, Gülicher D, Gerlach K, et al. Secretion of TFF-peptides by human salivary glands. Cell tissue Res. 1999;298:161–6.
Wiede A, Hinz M, Canzler E, Franke K, Quednow C, Hoffmann W. Synthesis and localization of the mucin-associated TFF-peptides in the human uterus. Cell Tissue Res. 2001;303:109–15.
Vestergaard E, Nexo E, Wendt A, Guthmann F. Trefoil factors in human milk. Early Hum Dev. 2008;84:631–5.
Langer G, Walter S, Behrens-Baumann W, Hoffmann W. [TFF peptides. New mucus-associated secretory products of the conjunctiva]. Der Ophthalmologe: Zeitschrift der Deutschen Ophthalmologischen Gesellschaft. 2001;98:976–9..
Paulsen F, Hinz M, Schaudig U, Thale A, Hoffmann W. TFF peptides in the human efferent tear ducts. Invest Ophthalmol Vis Sci. 2002;43:3359–64.
Steven P, Schäfer G, Nölle B, Hinz M, Hoffmann W, Paulsen F. Distribution of TFF peptides in corneal disease and pterygium. Peptides. 2004;25:819–25.
Taupin D, Kinoshita K, Podolsky D. Intestinal trefoil factor confers colonic epithelial resistance to apoptosis. Proc Natl Acad Sci USA. 2000;97:799–804.
Fu T, Znalesniak E, Kalinski T, Möhle L, Biswas A, Salm F, et al. TFF peptides play a role in the immune response following oral infection of mice with toxoplasma gondii. Eur J Microbiol Immunol. 2015;5:221–31.
Taupin D, Wu D, Jeon W, Devaney K, Wang T, Podolsky D. The trefoil gene family are coordinately expressed immediate-early genes: EGF receptor- and MAP kinase-dependent interregulation. J Clin Invest. 1999;103:R31–38.
Yu K, Jiang S, Lin M, Wu J, Lin J. Extraction and purification of biologically active intestinal trefoil factor from human meconium. Lab Invest. 2004;84:390–2.
Kjellev S, Nexø E, Thim L, Poulsen S. Systemically administered trefoil factors are secreted into the gastric lumen and increase the viscosity of gastric contents. Br J Pharmacol. 2006;149:92–99.
Zhang B, Yu H, Sheng Z, Luo H, Yu J. The therapeutic effect of recombinant human trefoil factor 3 on hypoxia-induced necrotizing enterocolitis in immature rat. Regulatory Pept. 2003;116:53–60.
Kjellev S, Thim L, Pyke C, Poulsen S. Cellular localization, binding sites, and pharmacologic effects of TFF3 in experimental colitis in mice. Digestive Dis Sci. 2007;52:1050–9.
Limaye S, Haddad R, Cilli F, Sonis S, Colevas A, Brennan M, et al. Phase 1b, multicenter, single blinded, placebo-controlled, sequential dose escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer receiving induction chemotherapy. Cancer. 2013;119:4268–76.